Cayman
Showing 37351–37500 of 45550 results
-
Radezolid is an oxazolidinone antibiotic and a derivative of linezolid (Item No. 15012).{46800} It is active against a variety of bacterial clinical isolates, including strains of methicillin-sensitive and -resistant S. aureus, vancomycin-sensitive and -resistant E. faecalis and E. faecium, and linezolid-resistant S. aureus, S. epidermidis, E. faecalis, E. faecium, and S. pneumoniae (MICs = ≤0.25-64 µg/ml). Radezolid is also active against L. monocytogenes, S. aureus, L. pneumophila, and S. epidermidis in THP-1 macrophages (EC50s = 0.62, 0.63, 8.45, and 2.99 mg/L, respectively).{46801} It inhibits protein translation in isolated wild-type and linezolid-resistant S. aureus 70S ribosomes but not rabbit reticulocyte lysates (IC50s = 0.02, 0.03, and >2 µM, respectively).{46802} Radezolid is efficacious in a mouse model of S. pneumoniae-induced peritonitis with a 50% protective dose (PD50) value of 1.3 mg/kg per day.{46803}
Brand:CaymanSKU:30092 - 5 mgAvailable on backorder
Radicicol is an inhibitor of heat shock protein 90 (Hsp90; IC50 = erb82, and mutant p53.{16758,16759} Radicicol also binds to and inhibits DNA topoisomerase type II proteins and GRP94 through an ATPase domain common to Hsp90.{16758,16756}
Brand:CaymanSKU:- Radicicol is an inhibitor of heat shock protein 90 (Hsp90; IC50 = erb82, and mutant p53.{16758,16759} Radicicol also binds to and inhibits DNA topoisomerase type II proteins and GRP94 through an ATPase domain common to Hsp90.{16758,16756}
Brand:CaymanSKU:- Radicicol is an inhibitor of heat shock protein 90 (Hsp90; IC50 = erb82, and mutant p53.{16758,16759} Radicicol also binds to and inhibits DNA topoisomerase type II proteins and GRP94 through an ATPase domain common to Hsp90.{16758,16756}
Brand:CaymanSKU:-
Brand:CaymanSKU:29861 - 1 mgAvailable on backorder
Brand:CaymanSKU:29861 - 5 mgAvailable on backorder
Radiprodil is an antagonist of NR2B subunit-containing NMDA receptors (IC50 = 8 nM).{52284} It is selective for NR2B subunit-containing NMDA receptors over NR1 and NR2A subunit-containing NMDA receptors at 15 µM. Radiprodil (10 nM) reduces amyloid β (1-42) (Aβ42) and Aβ40-induced decreases in dendritic spine density in mouse hippocampal CA1 pyramidal neurons.{52285} Radiprodil (2 mg/kg) restores novel object-stimulated locomotion in a marmoset model of MPTP-induced Parkinson’s disease.{47789}
Brand:CaymanSKU:29712 - 10 mgAvailable on backorder
Radiprodil is an antagonist of NR2B subunit-containing NMDA receptors (IC50 = 8 nM).{52284} It is selective for NR2B subunit-containing NMDA receptors over NR1 and NR2A subunit-containing NMDA receptors at 15 µM. Radiprodil (10 nM) reduces amyloid β (1-42) (Aβ42) and Aβ40-induced decreases in dendritic spine density in mouse hippocampal CA1 pyramidal neurons.{52285} Radiprodil (2 mg/kg) restores novel object-stimulated locomotion in a marmoset model of MPTP-induced Parkinson’s disease.{47789}
Brand:CaymanSKU:29712 - 25 mgAvailable on backorder
Radiprodil is an antagonist of NR2B subunit-containing NMDA receptors (IC50 = 8 nM).{52284} It is selective for NR2B subunit-containing NMDA receptors over NR1 and NR2A subunit-containing NMDA receptors at 15 µM. Radiprodil (10 nM) reduces amyloid β (1-42) (Aβ42) and Aβ40-induced decreases in dendritic spine density in mouse hippocampal CA1 pyramidal neurons.{52285} Radiprodil (2 mg/kg) restores novel object-stimulated locomotion in a marmoset model of MPTP-induced Parkinson’s disease.{47789}
Brand:CaymanSKU:29712 - 5 mgAvailable on backorder
Radiprodil is an antagonist of NR2B subunit-containing NMDA receptors (IC50 = 8 nM).{52284} It is selective for NR2B subunit-containing NMDA receptors over NR1 and NR2A subunit-containing NMDA receptors at 15 µM. Radiprodil (10 nM) reduces amyloid β (1-42) (Aβ42) and Aβ40-induced decreases in dendritic spine density in mouse hippocampal CA1 pyramidal neurons.{52285} Radiprodil (2 mg/kg) restores novel object-stimulated locomotion in a marmoset model of MPTP-induced Parkinson’s disease.{47789}
Brand:CaymanSKU:29712 - 50 mgAvailable on backorder
Radotinib is a selective second generation tyrosine kinase inhibitor that targets both the wild-type and mutant forms of Bcr-Abl, with an IC50 value of 30.6 nM in Ba/F3 human chronic myeloid leukemia cells expressing the wild-type form.{38002} Radotinib also inhibits platelet-derived growth factor receptors (PDGFRs) α and β with IC50 values of 75.5 and 130 nM, respectively.{38000,38001} Binding of radotinib to Bcr-Abl in vitro inhibits the phosphorylation of the downstream signaling mediator CrkL.{38001} In acute myeloid leukemia cells, in vitro treatment with radotinib at doses of 10-100 µM reduces viability, activates the mitochondrial apoptosis pathway, and promotes expression of the differentiation marker CD11b.{38000}
Brand:CaymanSKU:19923 -Available on backorder
Radotinib is a selective second generation tyrosine kinase inhibitor that targets both the wild-type and mutant forms of Bcr-Abl, with an IC50 value of 30.6 nM in Ba/F3 human chronic myeloid leukemia cells expressing the wild-type form.{38002} Radotinib also inhibits platelet-derived growth factor receptors (PDGFRs) α and β with IC50 values of 75.5 and 130 nM, respectively.{38000,38001} Binding of radotinib to Bcr-Abl in vitro inhibits the phosphorylation of the downstream signaling mediator CrkL.{38001} In acute myeloid leukemia cells, in vitro treatment with radotinib at doses of 10-100 µM reduces viability, activates the mitochondrial apoptosis pathway, and promotes expression of the differentiation marker CD11b.{38000}
Brand:CaymanSKU:19923 -Available on backorder
Radotinib is a selective second generation tyrosine kinase inhibitor that targets both the wild-type and mutant forms of Bcr-Abl, with an IC50 value of 30.6 nM in Ba/F3 human chronic myeloid leukemia cells expressing the wild-type form.{38002} Radotinib also inhibits platelet-derived growth factor receptors (PDGFRs) α and β with IC50 values of 75.5 and 130 nM, respectively.{38000,38001} Binding of radotinib to Bcr-Abl in vitro inhibits the phosphorylation of the downstream signaling mediator CrkL.{38001} In acute myeloid leukemia cells, in vitro treatment with radotinib at doses of 10-100 µM reduces viability, activates the mitochondrial apoptosis pathway, and promotes expression of the differentiation marker CD11b.{38000}
Brand:CaymanSKU:19923 -Available on backorder
Radotinib is a selective second generation tyrosine kinase inhibitor that targets both the wild-type and mutant forms of Bcr-Abl, with an IC50 value of 30.6 nM in Ba/F3 human chronic myeloid leukemia cells expressing the wild-type form.{38002} Radotinib also inhibits platelet-derived growth factor receptors (PDGFRs) α and β with IC50 values of 75.5 and 130 nM, respectively.{38000,38001} Binding of radotinib to Bcr-Abl in vitro inhibits the phosphorylation of the downstream signaling mediator CrkL.{38001} In acute myeloid leukemia cells, in vitro treatment with radotinib at doses of 10-100 µM reduces viability, activates the mitochondrial apoptosis pathway, and promotes expression of the differentiation marker CD11b.{38000}
Brand:CaymanSKU:19923 -Available on backorder
The Ras pathway is a critical signal transduction cascade involved in regulating cellular proliferation, differentiation, survival, and oncogenic transformation. Members of the Raf serine/threonine kinase family are key intermediates in this cascade, functioning to relay signals from activated Ras to the downstream protein kinases MEK and ERK.{14542} Previous studies have shown that phosphorylation is required for Raf-1 activation.{14329,14539} Recent work has demonstrated that phosphorylation also regulates the down regulation of Raf with two sites participating: Ser301 and Ser642.{14540}
Brand:CaymanSKU:10009504 - 1 eaAvailable on backorder
Antigen: phosphopeptide corresponding to amino acid residues surrounding phospho-Ser301 of rat Raf-1 • Host: rabbit • Cross Reactivity: (+) rat Raf-1; expected to react with bovine, canine, chicken, human, mouse, non-human primate, and Xenopus Raf-1 • Application(s): WB • Studies have shown that phosphorylation is required for Raf-1 activation. Phosphorylation also down-regulates Raf with two sites participating: Ser301 and Ser642.
Brand:CaymanSKU:10009504- 1 eaAvailable on backorder
Antigen: phosphopeptide corresponding to amino acid residues surrounding phospho-Ser301 of rat Raf-1 • Host: rabbit • Cross Reactivity: (+) rat Raf-1; expected to react with bovine, canine, chicken, human, mouse, non-human primate, and Xenopus Raf-1 • Application(s): WB • Studies have shown that phosphorylation is required for Raf-1 activation. Phosphorylation also down-regulates Raf with two sites participating: Ser301 and Ser642.
Brand:CaymanSKU:10009504- 1 ea The Ras pathway is a critical signal transduction cascade involved in regulating cellular proliferation, differentiation, survival, and oncogenic transformation. Members of the Raf serine/threonine kinase family are key intermediates in this cascade, functioning to relay signals from activated Ras to the downstream protein kinases MEK and ERK.{14542} Previous studies have shown that phosphorylation is required for Raf-1 activation.{14329,14539} Recent work has demonstrated that phosphorylation also regulates the down regulation of Raf with two sites participating: Ser301 and Ser642.{14540}
Brand:CaymanSKU:10009505 - 1 eaAvailable on backorder
Antigen: phosphopeptide corresponding to amino acid residues surrounding phospho-Ser642 of rat raf-1 • Host: rabbit • Cross Reactivity: (+) rat raf-1; expected to react with bovine, canine, chicken, human, mouse, non-human primate, and Xenopus raf-1 • Application(s): WB • Members of the Raf serine/threonine kinase family function to relay signals from activated Ras to the downstream protein kinases MEK and ERK, which are critical for cellular proliferation, differentiation, survival, and oncogenic transformation. RAf-1 activity is regulated by phophorylation of Ser301 and Ser642.
Brand:CaymanSKU:10009505- 1 eaAvailable on backorder
Antigen: phosphopeptide corresponding to amino acid residues surrounding phospho-Ser642 of rat raf-1 • Host: rabbit • Cross Reactivity: (+) rat raf-1; expected to react with bovine, canine, chicken, human, mouse, non-human primate, and Xenopus raf-1 • Application(s): WB • Members of the Raf serine/threonine kinase family function to relay signals from activated Ras to the downstream protein kinases MEK and ERK, which are critical for cellular proliferation, differentiation, survival, and oncogenic transformation. RAf-1 activity is regulated by phophorylation of Ser301 and Ser642.
Brand:CaymanSKU:10009505- 1 ea
RAF265 is a dual inhibitor of mutant B-RafV600E and vascular endothelial growth factor receptor 2 (EC50s = 0.14 and 0.19 µM, respectively, in cell-based assays).{27852} It can also inhibit wild-type B-Raf, platelet-derived growth factor receptor, colony-stimulating factor 1R, RET, c-KIT, SRC, and STE20 with IC50 values ranging from 20-100 nM.{27957} RAF265 can inhibit proliferation of melanoma and colorectal cancer cell lines with active BRAF mutations as well as suppress tumor growth in melanoma xenograft models bearing B-RafV600E mutations.{27957}
Brand:CaymanSKU:-Out of stock
RAF265 is a dual inhibitor of mutant B-RafV600E and vascular endothelial growth factor receptor 2 (EC50s = 0.14 and 0.19 µM, respectively, in cell-based assays).{27852} It can also inhibit wild-type B-Raf, platelet-derived growth factor receptor, colony-stimulating factor 1R, RET, c-KIT, SRC, and STE20 with IC50 values ranging from 20-100 nM.{27957} RAF265 can inhibit proliferation of melanoma and colorectal cancer cell lines with active BRAF mutations as well as suppress tumor growth in melanoma xenograft models bearing B-RafV600E mutations.{27957}
Brand:CaymanSKU:-Out of stock
RAF265 is a dual inhibitor of mutant B-RafV600E and vascular endothelial growth factor receptor 2 (EC50s = 0.14 and 0.19 µM, respectively, in cell-based assays).{27852} It can also inhibit wild-type B-Raf, platelet-derived growth factor receptor, colony-stimulating factor 1R, RET, c-KIT, SRC, and STE20 with IC50 values ranging from 20-100 nM.{27957} RAF265 can inhibit proliferation of melanoma and colorectal cancer cell lines with active BRAF mutations as well as suppress tumor growth in melanoma xenograft models bearing B-RafV600E mutations.{27957}
Brand:CaymanSKU:-Out of stock
RAF265 is a dual inhibitor of mutant B-RafV600E and vascular endothelial growth factor receptor 2 (EC50s = 0.14 and 0.19 µM, respectively, in cell-based assays).{27852} It can also inhibit wild-type B-Raf, platelet-derived growth factor receptor, colony-stimulating factor 1R, RET, c-KIT, SRC, and STE20 with IC50 values ranging from 20-100 nM.{27957} RAF265 can inhibit proliferation of melanoma and colorectal cancer cell lines with active BRAF mutations as well as suppress tumor growth in melanoma xenograft models bearing B-RafV600E mutations.{27957}
Brand:CaymanSKU:-Out of stock
RAF709 is a potent inhibitor of B-RAF and C-RAF (IC50s = 0.4 and 0.5 nM, respectively).{37294} It is selective for RAF kinases exhibiting >99% inhibition of only B-RAF, B-RAFV600E, and C-RAF in a panel of 456 kinases. However, DDR1, DDR2, FRK, and PDGFRβ are also inhibited by >80% at a concentration of 1 μM. RAF709 inhibits phosphorylation of MEK and ERK (EC50s = 0.02 and 0.1 μM, respectively) with minimal paradoxical activation, stabilizes BRAF-CRAF dimers (EC50 = 0.8 μM), and reduces proliferation of Calu-6 RAS mutant cells (EC50 = 0.95 μM). In a Calu-6 mouse non-small cell lung cancer (NSCLC) xenograft model, RAF709 (10-200 mg/kg) reduces ERK phosphorylation and decreases tumor volume in a dose-dependent manner without affecting total body weight.
Brand:CaymanSKU:23820 - 1 mgAvailable on backorder
RAF709 is a potent inhibitor of B-RAF and C-RAF (IC50s = 0.4 and 0.5 nM, respectively).{37294} It is selective for RAF kinases exhibiting >99% inhibition of only B-RAF, B-RAFV600E, and C-RAF in a panel of 456 kinases. However, DDR1, DDR2, FRK, and PDGFRβ are also inhibited by >80% at a concentration of 1 μM. RAF709 inhibits phosphorylation of MEK and ERK (EC50s = 0.02 and 0.1 μM, respectively) with minimal paradoxical activation, stabilizes BRAF-CRAF dimers (EC50 = 0.8 μM), and reduces proliferation of Calu-6 RAS mutant cells (EC50 = 0.95 μM). In a Calu-6 mouse non-small cell lung cancer (NSCLC) xenograft model, RAF709 (10-200 mg/kg) reduces ERK phosphorylation and decreases tumor volume in a dose-dependent manner without affecting total body weight.
Brand:CaymanSKU:23820 - 10 mgAvailable on backorder
RAF709 is a potent inhibitor of B-RAF and C-RAF (IC50s = 0.4 and 0.5 nM, respectively).{37294} It is selective for RAF kinases exhibiting >99% inhibition of only B-RAF, B-RAFV600E, and C-RAF in a panel of 456 kinases. However, DDR1, DDR2, FRK, and PDGFRβ are also inhibited by >80% at a concentration of 1 μM. RAF709 inhibits phosphorylation of MEK and ERK (EC50s = 0.02 and 0.1 μM, respectively) with minimal paradoxical activation, stabilizes BRAF-CRAF dimers (EC50 = 0.8 μM), and reduces proliferation of Calu-6 RAS mutant cells (EC50 = 0.95 μM). In a Calu-6 mouse non-small cell lung cancer (NSCLC) xenograft model, RAF709 (10-200 mg/kg) reduces ERK phosphorylation and decreases tumor volume in a dose-dependent manner without affecting total body weight.
Brand:CaymanSKU:23820 - 5 mgAvailable on backorder
Rafoxanide is an anthelmintic.{52259,52260,52261} In vivo, rafoxanide (50 mg/kg) completely eradicates E. caproni infection in mice.{52259} It is active against H. contortus in sheep when administered at a dose of 10 mg/kg and eliminates mature F. hepatica flukes in cattle when administered at a dose of 7.5 mg/kg.{52260,52261} It is also cytotoxic to A375 and A431 skin cancer cells in vitro (IC50s = 10.9 and 1.31 µM, respectively) and reduces tumor growth in an A375 mouse xenograft model when administered at a dose of 40 mg/kg.{52261} Formulations containing rafoxanide have been used in the treatment of parasitic infections in sheep and cattle.
Brand:CaymanSKU:29616 - 1 gAvailable on backorder
Rafoxanide is an anthelmintic.{52259,52260,52261} In vivo, rafoxanide (50 mg/kg) completely eradicates E. caproni infection in mice.{52259} It is active against H. contortus in sheep when administered at a dose of 10 mg/kg and eliminates mature F. hepatica flukes in cattle when administered at a dose of 7.5 mg/kg.{52260,52261} It is also cytotoxic to A375 and A431 skin cancer cells in vitro (IC50s = 10.9 and 1.31 µM, respectively) and reduces tumor growth in an A375 mouse xenograft model when administered at a dose of 40 mg/kg.{52261} Formulations containing rafoxanide have been used in the treatment of parasitic infections in sheep and cattle.
Brand:CaymanSKU:29616 - 250 mgAvailable on backorder
Rafoxanide is an anthelmintic.{52259,52260,52261} In vivo, rafoxanide (50 mg/kg) completely eradicates E. caproni infection in mice.{52259} It is active against H. contortus in sheep when administered at a dose of 10 mg/kg and eliminates mature F. hepatica flukes in cattle when administered at a dose of 7.5 mg/kg.{52260,52261} It is also cytotoxic to A375 and A431 skin cancer cells in vitro (IC50s = 10.9 and 1.31 µM, respectively) and reduces tumor growth in an A375 mouse xenograft model when administered at a dose of 40 mg/kg.{52261} Formulations containing rafoxanide have been used in the treatment of parasitic infections in sheep and cattle.
Brand:CaymanSKU:29616 - 500 mgAvailable on backorder
Ralinepag is a prostaglandin I2 (PGI2) receptor (IP) agonist (Ki = 3 nM).{50853} It is selective for IP over the PGD2 receptor (DP1) and the PGE2 receptor subtypes EP1-4 (Kis = 2,600, 9,600, 611, 143, and 678 nM, respectively, in radioligand binding assays). Ralinepag induces cAMP accumulation in CHO-K1 cells expressing human recombinant IP (EC50 = 8.5 nM). In vivo, ralinepag (30 mg/kg) prevents increases in pulmonary arterial pressure and vessel wall thickness in a rat model of monocrotaline-induced pulmonary arterial hypertension.
Brand:CaymanSKU:30009 - 1 mgAvailable on backorder
Ralinepag is a prostaglandin I2 (PGI2) receptor (IP) agonist (Ki = 3 nM).{50853} It is selective for IP over the PGD2 receptor (DP1) and the PGE2 receptor subtypes EP1-4 (Kis = 2,600, 9,600, 611, 143, and 678 nM, respectively, in radioligand binding assays). Ralinepag induces cAMP accumulation in CHO-K1 cells expressing human recombinant IP (EC50 = 8.5 nM). In vivo, ralinepag (30 mg/kg) prevents increases in pulmonary arterial pressure and vessel wall thickness in a rat model of monocrotaline-induced pulmonary arterial hypertension.
Brand:CaymanSKU:30009 - 10 mgAvailable on backorder
Ralinepag is a prostaglandin I2 (PGI2) receptor (IP) agonist (Ki = 3 nM).{50853} It is selective for IP over the PGD2 receptor (DP1) and the PGE2 receptor subtypes EP1-4 (Kis = 2,600, 9,600, 611, 143, and 678 nM, respectively, in radioligand binding assays). Ralinepag induces cAMP accumulation in CHO-K1 cells expressing human recombinant IP (EC50 = 8.5 nM). In vivo, ralinepag (30 mg/kg) prevents increases in pulmonary arterial pressure and vessel wall thickness in a rat model of monocrotaline-induced pulmonary arterial hypertension.
Brand:CaymanSKU:30009 - 25 mgAvailable on backorder
Ralinepag is a prostaglandin I2 (PGI2) receptor (IP) agonist (Ki = 3 nM).{50853} It is selective for IP over the PGD2 receptor (DP1) and the PGE2 receptor subtypes EP1-4 (Kis = 2,600, 9,600, 611, 143, and 678 nM, respectively, in radioligand binding assays). Ralinepag induces cAMP accumulation in CHO-K1 cells expressing human recombinant IP (EC50 = 8.5 nM). In vivo, ralinepag (30 mg/kg) prevents increases in pulmonary arterial pressure and vessel wall thickness in a rat model of monocrotaline-induced pulmonary arterial hypertension.
Brand:CaymanSKU:30009 - 5 mgAvailable on backorder
Raloxifene (hydrochloride) (Item No. 27189) is an analytical reference standard categorized as a selective estrogen receptor modulator (SERM).{42731} It has been detected as an adverse analytical finding (AAF) during anti-doping testing.{48164} This product is intended for use in analytical forensic applications. This product is also available as a general research tool (Item No. 10011620).
Brand:CaymanSKU:27189 - 10 mgAvailable on backorder
Raloxifene is a selective estrogen receptor modulator (SERM) that binds to the estrogen receptor with an IC50 value of 0.4 nM.{42731} It exhibits estrogenic activity in bone cells without stimulating breast or uterine tissues.{16603} Raloxifene guards endothelial cells obtained from rat aortic rings against oxidative insult (1 µM) and lowers serum cholesterol in ovariectomized rodents (ED50 = 0.2 mg/kg).{16603,16602} Raloxifene also inhibits the voltage-gated potassium channel Kv4.3 in an estrogen-independent manner (IC50 = 2 µM).{42733} Formulations containing raloxifene have been shown to reduce bone resorption and promote bone formation in post-menopausal women.{16604}
Brand:CaymanSKU:10011620 - 100 mgAvailable on backorder
Raloxifene (hydrochloride) (Item No. 27189) is an analytical reference standard categorized as a selective estrogen receptor modulator (SERM).{42731} It has been detected as an adverse analytical finding (AAF) during anti-doping testing.{48164} This product is intended for use in analytical forensic applications. This product is also available as a general research tool (Item No. 10011620).
Brand:CaymanSKU:27189 - 25 mgAvailable on backorder
Raloxifene is a selective estrogen receptor modulator (SERM) that binds to the estrogen receptor with an IC50 value of 0.4 nM.{42731} It exhibits estrogenic activity in bone cells without stimulating breast or uterine tissues.{16603} Raloxifene guards endothelial cells obtained from rat aortic rings against oxidative insult (1 µM) and lowers serum cholesterol in ovariectomized rodents (ED50 = 0.2 mg/kg).{16603,16602} Raloxifene also inhibits the voltage-gated potassium channel Kv4.3 in an estrogen-independent manner (IC50 = 2 µM).{42733} Formulations containing raloxifene have been shown to reduce bone resorption and promote bone formation in post-menopausal women.{16604}
Brand:CaymanSKU:10011620 - 250 mgAvailable on backorder
Raloxifene (hydrochloride) (Item No. 27189) is an analytical reference standard categorized as a selective estrogen receptor modulator (SERM).{42731} It has been detected as an adverse analytical finding (AAF) during anti-doping testing.{48164} This product is intended for use in analytical forensic applications. This product is also available as a general research tool (Item No. 10011620).
Brand:CaymanSKU:27189 - 5 mgAvailable on backorder
Raloxifene is a selective estrogen receptor modulator (SERM) that binds to the estrogen receptor with an IC50 value of 0.4 nM.{42731} It exhibits estrogenic activity in bone cells without stimulating breast or uterine tissues.{16603} Raloxifene guards endothelial cells obtained from rat aortic rings against oxidative insult (1 µM) and lowers serum cholesterol in ovariectomized rodents (ED50 = 0.2 mg/kg).{16603,16602} Raloxifene also inhibits the voltage-gated potassium channel Kv4.3 in an estrogen-independent manner (IC50 = 2 µM).{42733} Formulations containing raloxifene have been shown to reduce bone resorption and promote bone formation in post-menopausal women.{16604}
Brand:CaymanSKU:10011620 - 50 mgAvailable on backorder
Raloxifene (hydrochloride) (Item No. 27189) is an analytical reference standard categorized as a selective estrogen receptor modulator (SERM).{42731} It has been detected as an adverse analytical finding (AAF) during anti-doping testing.{48164} This product is intended for use in analytical forensic applications. This product is also available as a general research tool (Item No. 10011620).
Brand:CaymanSKU:27189 - 50 mgAvailable on backorder
Raloxifene is a selective estrogen receptor modulator (SERM) that binds to the estrogen receptor with an IC50 value of 0.4 nM.{42731} It exhibits estrogenic activity in bone cells without stimulating breast or uterine tissues.{16603} Raloxifene guards endothelial cells obtained from rat aortic rings against oxidative insult (1 µM) and lowers serum cholesterol in ovariectomized rodents (ED50 = 0.2 mg/kg).{16603,16602} Raloxifene also inhibits the voltage-gated potassium channel Kv4.3 in an estrogen-independent manner (IC50 = 2 µM).{42733} Formulations containing raloxifene have been shown to reduce bone resorption and promote bone formation in post-menopausal women.{16604}
Brand:CaymanSKU:10011620 - 500 mgAvailable on backorder
Raloxifene 4’-glucuronide is a metabolite of the selective estrogen receptor modulator raloxifene (Item No. 10011620).{42731} It is formed from raloxifene via the UDP-glucuronosyltransferase (UGT) isoforms UGT1A1, UGT1A8, and UGT1A10.{42732} It binds to the estrogen receptor with an IC50 value of 370 nM.{42731} Raloxifene 4’-glucuronide inhibits the voltage-gated potassium channel Kv4.3 by 6.2 and 20.1% when used at concentrations of 10 and 30 µM, respectively.{42733}
Brand:CaymanSKU:27831 - 1 mgAvailable on backorder
Raloxifene 6-glucuronide is a metabolite of the selective estrogen receptor modulator raloxifene (Item No. 10011620).{42731} It is formed from raloxifene via the UDP-glucuronosyltransferase (UGT) isoforms UGT1A1 and UGT1A8. It binds to the estrogen receptor with an IC50 value of 290 nM.{42731,42732} Unlike raloxifene, raloxifene 6-glucuronide does not inhibit the voltage-gated potassium channel Kv4.3.{42733}
Brand:CaymanSKU:27832 - 1 mgAvailable on backorder
Raloxifene-d4 is intended for use as an internal standard for the quantification of raloxifene (Item No. 10011620) by GC- or LC-MS. Raloxifene is a selective estrogen receptor modulator (SERM) that exhibits estrogenic activity in bone cells without stimulating breast or uterine tissues.{16603} Raloxifene guards endothelial cells obtained from rat aortic rings against oxidative insult (1 µM) and lowers serum cholesterol in ovariectomized rodents (ED50 = 0.2 mg/kg).{16602,16603} Formulations containing raloxifene have been shown to reduce bone resorption and promote bone formation in post-menopausal women.{16604}
Brand:CaymanSKU:22900 - 1 mgAvailable on backorder
Raloxifene-d4 is intended for use as an internal standard for the quantification of raloxifene (Item No. 10011620) by GC- or LC-MS. Raloxifene is a selective estrogen receptor modulator (SERM) that exhibits estrogenic activity in bone cells without stimulating breast or uterine tissues.{16603} Raloxifene guards endothelial cells obtained from rat aortic rings against oxidative insult (1 µM) and lowers serum cholesterol in ovariectomized rodents (ED50 = 0.2 mg/kg).{16602,16603} Formulations containing raloxifene have been shown to reduce bone resorption and promote bone formation in post-menopausal women.{16604}
Brand:CaymanSKU:22900 - 5 mgAvailable on backorder
Raloxifene-d4 is intended for use as an internal standard for the quantification of raloxifene (Item No. 10011620) by GC- or LC-MS. Raloxifene is a selective estrogen receptor modulator (SERM) that exhibits estrogenic activity in bone cells without stimulating breast or uterine tissues.{16603} Raloxifene guards endothelial cells obtained from rat aortic rings against oxidative insult (1 µM) and lowers serum cholesterol in ovariectomized rodents (ED50 = 0.2 mg/kg).{16602,16603} Formulations containing raloxifene have been shown to reduce bone resorption and promote bone formation in post-menopausal women.{16604}
Brand:CaymanSKU:22900 - 500 µgAvailable on backorder
Raltegravir is an orally bioavailable inhibitor of HIV-1 integrase (IC50 = 15 nM in a strand transfer assay).{26192} It inhibits the spread of HIV-1IIIb infection in MT-4 cell culture with 95% cell culture inhibitory concentration (CIC95) values of 19 and 31 nM in medium containing 10% heat-inactivated fetal bovine serum (FBS) or 50% normal human serum, respectively. Formulations containing raltegravir have been used in combination therapy in the treatment of HIV-1 infection.
Brand:CaymanSKU:- Raltegravir is an orally bioavailable inhibitor of HIV-1 integrase (IC50 = 15 nM in a strand transfer assay).{26192} It inhibits the spread of HIV-1IIIb infection in MT-4 cell culture with 95% cell culture inhibitory concentration (CIC95) values of 19 and 31 nM in medium containing 10% heat-inactivated fetal bovine serum (FBS) or 50% normal human serum, respectively. Formulations containing raltegravir have been used in combination therapy in the treatment of HIV-1 infection.
Brand:CaymanSKU:- Raltegravir is an orally bioavailable inhibitor of HIV-1 integrase (IC50 = 15 nM in a strand transfer assay).{26192} It inhibits the spread of HIV-1IIIb infection in MT-4 cell culture with 95% cell culture inhibitory concentration (CIC95) values of 19 and 31 nM in medium containing 10% heat-inactivated fetal bovine serum (FBS) or 50% normal human serum, respectively. Formulations containing raltegravir have been used in combination therapy in the treatment of HIV-1 infection.
Brand:CaymanSKU:- Raltegravir is an orally bioavailable inhibitor of HIV-1 integrase (IC50 = 15 nM in a strand transfer assay).{26192} It inhibits the spread of HIV-1IIIb infection in MT-4 cell culture with 95% cell culture inhibitory concentration (CIC95) values of 19 and 31 nM in medium containing 10% heat-inactivated fetal bovine serum (FBS) or 50% normal human serum, respectively. Formulations containing raltegravir have been used in combination therapy in the treatment of HIV-1 infection.
Brand:CaymanSKU:-
Raltitrexed is an inhibitor of thymidylate synthase (Ki = 62 nM).{36978} It inhibits the growth of L1210 mouse lymphocytic leukemia cells in vitro (IC50 = 8 nM) as well as reduces thymidylate synthase activity and completely eliminates tumors in a mouse L1210:ICR ascitic tumor model when administered at a dose of 4 mg/kg, effects that can be reversed by administration of thymidine. It also reduces tumor growth and the number of metastases in an HCT116-luc mouse xenograft model.{36979} Formulations containing raltitrexed have been used in the treatment of advanced colorectal cancers.
Brand:CaymanSKU:26079 - 10 mgAvailable on backorder
Raltitrexed is an inhibitor of thymidylate synthase (Ki = 62 nM).{36978} It inhibits the growth of L1210 mouse lymphocytic leukemia cells in vitro (IC50 = 8 nM) as well as reduces thymidylate synthase activity and completely eliminates tumors in a mouse L1210:ICR ascitic tumor model when administered at a dose of 4 mg/kg, effects that can be reversed by administration of thymidine. It also reduces tumor growth and the number of metastases in an HCT116-luc mouse xenograft model.{36979} Formulations containing raltitrexed have been used in the treatment of advanced colorectal cancers.
Brand:CaymanSKU:26079 - 100 mgAvailable on backorder
Raltitrexed is an inhibitor of thymidylate synthase (Ki = 62 nM).{36978} It inhibits the growth of L1210 mouse lymphocytic leukemia cells in vitro (IC50 = 8 nM) as well as reduces thymidylate synthase activity and completely eliminates tumors in a mouse L1210:ICR ascitic tumor model when administered at a dose of 4 mg/kg, effects that can be reversed by administration of thymidine. It also reduces tumor growth and the number of metastases in an HCT116-luc mouse xenograft model.{36979} Formulations containing raltitrexed have been used in the treatment of advanced colorectal cancers.
Brand:CaymanSKU:26079 - 25 mgAvailable on backorder
Raltitrexed is an inhibitor of thymidylate synthase (Ki = 62 nM).{36978} It inhibits the growth of L1210 mouse lymphocytic leukemia cells in vitro (IC50 = 8 nM) as well as reduces thymidylate synthase activity and completely eliminates tumors in a mouse L1210:ICR ascitic tumor model when administered at a dose of 4 mg/kg, effects that can be reversed by administration of thymidine. It also reduces tumor growth and the number of metastases in an HCT116-luc mouse xenograft model.{36979} Formulations containing raltitrexed have been used in the treatment of advanced colorectal cancers.
Brand:CaymanSKU:26079 - 50 mgAvailable on backorder
Ramelteon is a melatonin (MT) receptor agonist (Kis = 14, 112, and 23.1 pM for human MT1, human MT2, and chick forebrain receptors, respectively).{42292} It is selective for MT1 and MT2 over MT3 receptors (Ki = 2.65 μM for hamster brain MT3 receptors) as well as a panel of benzodiazepine, dopamine, and opiate receptors, ion channels, transporters, and enzymes when used at a concentration of 10 μM. Ramelteon stimulates cAMP production in CHO cells expressing human MT1 and MT2 receptors (IC50s = 21.2 and 53.4 pM, respectively). In vivo, ramelteon (0.03 and 0.3 mg/kg, p.o.) shortens latency to sleep onset and increases duration of sleep in free-moving crab-eating macaques.{42293} It also accelerates reentrainment of circadian rhythm in rats, shifting running wheel activity back to the dark period 2.4 and 3 days more quickly than vehicle-treated animals following an eight-hour phase shift in the light-dark cycle when administered at 0.1 and 1 mg/kg, respectively, with no effect on learinng and memory in the Morris water maze and delayed match-to-position tasks.{42294}
Brand:CaymanSKU:20389 -Available on backorder
Ramelteon is a melatonin (MT) receptor agonist (Kis = 14, 112, and 23.1 pM for human MT1, human MT2, and chick forebrain receptors, respectively).{42292} It is selective for MT1 and MT2 over MT3 receptors (Ki = 2.65 μM for hamster brain MT3 receptors) as well as a panel of benzodiazepine, dopamine, and opiate receptors, ion channels, transporters, and enzymes when used at a concentration of 10 μM. Ramelteon stimulates cAMP production in CHO cells expressing human MT1 and MT2 receptors (IC50s = 21.2 and 53.4 pM, respectively). In vivo, ramelteon (0.03 and 0.3 mg/kg, p.o.) shortens latency to sleep onset and increases duration of sleep in free-moving crab-eating macaques.{42293} It also accelerates reentrainment of circadian rhythm in rats, shifting running wheel activity back to the dark period 2.4 and 3 days more quickly than vehicle-treated animals following an eight-hour phase shift in the light-dark cycle when administered at 0.1 and 1 mg/kg, respectively, with no effect on learinng and memory in the Morris water maze and delayed match-to-position tasks.{42294}
Brand:CaymanSKU:20389 -Available on backorder
Ramelteon is a melatonin (MT) receptor agonist (Kis = 14, 112, and 23.1 pM for human MT1, human MT2, and chick forebrain receptors, respectively).{42292} It is selective for MT1 and MT2 over MT3 receptors (Ki = 2.65 μM for hamster brain MT3 receptors) as well as a panel of benzodiazepine, dopamine, and opiate receptors, ion channels, transporters, and enzymes when used at a concentration of 10 μM. Ramelteon stimulates cAMP production in CHO cells expressing human MT1 and MT2 receptors (IC50s = 21.2 and 53.4 pM, respectively). In vivo, ramelteon (0.03 and 0.3 mg/kg, p.o.) shortens latency to sleep onset and increases duration of sleep in free-moving crab-eating macaques.{42293} It also accelerates reentrainment of circadian rhythm in rats, shifting running wheel activity back to the dark period 2.4 and 3 days more quickly than vehicle-treated animals following an eight-hour phase shift in the light-dark cycle when administered at 0.1 and 1 mg/kg, respectively, with no effect on learinng and memory in the Morris water maze and delayed match-to-position tasks.{42294}
Brand:CaymanSKU:20389 -Available on backorder
Ramipril is a prodrug form of the angiotensin-converting enzyme (ACE) inhibitor ramiprilat (Item No. 15557).{23056} Ramipril (2.5 mg/kg per day, p.o.) reduces systolic blood pressure in spontaneously hypertensive rats.{36825} It reduces aortic valve backscatter and improves aortic flow in a rabbit model of aortic valve stenosis.{36826} Ramipril also decreases paw swelling and serum levels of TNF-α and prostaglandin E2 (PGE2) as well as cardiac collagen deposition and fibrosis in a rat model of adjuvant-induced arthritis.{36827}
Brand:CaymanSKU:- Ramipril is a prodrug form of the angiotensin-converting enzyme (ACE) inhibitor ramiprilat (Item No. 15557).{23056} Ramipril (2.5 mg/kg per day, p.o.) reduces systolic blood pressure in spontaneously hypertensive rats.{36825} It reduces aortic valve backscatter and improves aortic flow in a rabbit model of aortic valve stenosis.{36826} Ramipril also decreases paw swelling and serum levels of TNF-α and prostaglandin E2 (PGE2) as well as cardiac collagen deposition and fibrosis in a rat model of adjuvant-induced arthritis.{36827}
Brand:CaymanSKU:- Ramipril is a prodrug form of the angiotensin-converting enzyme (ACE) inhibitor ramiprilat (Item No. 15557).{23056} Ramipril (2.5 mg/kg per day, p.o.) reduces systolic blood pressure in spontaneously hypertensive rats.{36825} It reduces aortic valve backscatter and improves aortic flow in a rabbit model of aortic valve stenosis.{36826} Ramipril also decreases paw swelling and serum levels of TNF-α and prostaglandin E2 (PGE2) as well as cardiac collagen deposition and fibrosis in a rat model of adjuvant-induced arthritis.{36827}
Brand:CaymanSKU:- Ramipril is a prodrug form of the angiotensin-converting enzyme (ACE) inhibitor ramiprilat (Item No. 15557).{23056} Ramipril (2.5 mg/kg per day, p.o.) reduces systolic blood pressure in spontaneously hypertensive rats.{36825} It reduces aortic valve backscatter and improves aortic flow in a rabbit model of aortic valve stenosis.{36826} Ramipril also decreases paw swelling and serum levels of TNF-α and prostaglandin E2 (PGE2) as well as cardiac collagen deposition and fibrosis in a rat model of adjuvant-induced arthritis.{36827}
Brand:CaymanSKU:-
Ramipril-d5 is intended for use as an internal standard for the quantification of ramipril (Item No. 15558) by GC- or LC-MS. Ramipril is a prodrug form of the angiotensin converting enzyme (ACE) inhibitor ramiprilat (Item No. 15557).{23056} Ramipril (2.5 mg/kg per day, p.o.) reduces systolic blood pressure in spontaneously hypertensive rats.{36825} It reduces aortic valve backscatter and improves aortic flow in a rabbit model of aortic valve stenosis.{36826} Ramipril also decreases paw swelling and serum levels of TNF-α and prostaglandin E2 (PGE2) as well as cardiac collagen deposition and fibrosis in a rat model of adjuvant-induced arthritis.{36827}
Brand:CaymanSKU:25425 - 1 mgAvailable on backorder
Ramipril-d5 is intended for use as an internal standard for the quantification of ramipril (Item No. 15558) by GC- or LC-MS. Ramipril is a prodrug form of the angiotensin converting enzyme (ACE) inhibitor ramiprilat (Item No. 15557).{23056} Ramipril (2.5 mg/kg per day, p.o.) reduces systolic blood pressure in spontaneously hypertensive rats.{36825} It reduces aortic valve backscatter and improves aortic flow in a rabbit model of aortic valve stenosis.{36826} Ramipril also decreases paw swelling and serum levels of TNF-α and prostaglandin E2 (PGE2) as well as cardiac collagen deposition and fibrosis in a rat model of adjuvant-induced arthritis.{36827}
Brand:CaymanSKU:25425 - 500 µgAvailable on backorder
Ramiprilat is the active metabolite of ramipril (Item No. 15558) and functions as an angiotensin-converting enzyme inhibitor (pKi = 9.08 in human heart) to suppress the conversion of angiotensin I to angiotensin II and the degradation of bradykinin, thereby preventing vasoconstriction.{30687,30685} Furthermore, ramiprilat is reported to interfere with the targeting of B2 kinin receptors to endothelial cell membranes further preventing bradykinin signaling.{30685} In addition to its cardioprotective effects in both animal models and clinical studies, ramiprilat has been reported to inhibit matrix metalloproteinase-3 and -9 activity in isolated Crohn’s disease fistulas.{25581,30686}
Brand:CaymanSKU:- Ramiprilat is the active metabolite of ramipril (Item No. 15558) and functions as an angiotensin-converting enzyme inhibitor (pKi = 9.08 in human heart) to suppress the conversion of angiotensin I to angiotensin II and the degradation of bradykinin, thereby preventing vasoconstriction.{30687,30685} Furthermore, ramiprilat is reported to interfere with the targeting of B2 kinin receptors to endothelial cell membranes further preventing bradykinin signaling.{30685} In addition to its cardioprotective effects in both animal models and clinical studies, ramiprilat has been reported to inhibit matrix metalloproteinase-3 and -9 activity in isolated Crohn’s disease fistulas.{25581,30686}
Brand:CaymanSKU:- Ramiprilat is the active metabolite of ramipril (Item No. 15558) and functions as an angiotensin-converting enzyme inhibitor (pKi = 9.08 in human heart) to suppress the conversion of angiotensin I to angiotensin II and the degradation of bradykinin, thereby preventing vasoconstriction.{30687,30685} Furthermore, ramiprilat is reported to interfere with the targeting of B2 kinin receptors to endothelial cell membranes further preventing bradykinin signaling.{30685} In addition to its cardioprotective effects in both animal models and clinical studies, ramiprilat has been reported to inhibit matrix metalloproteinase-3 and -9 activity in isolated Crohn’s disease fistulas.{25581,30686}
Brand:CaymanSKU:-
Ramoplanin complex is a mixture of ramoplanin A1, -A2, and -A3 originally isolated from Actinoplanes that has antibacterial activity.{46853,46854,46855} Ramoplanin complex is active against clinical isolates of the Gram-positive bacteria S. aureus, S. pyogenes, S. pneumoniae, and S. faecalis (MICs = 0.016-2 µg/ml) but not Gram-negative bacteria or C. albicans (MICs = ≥128 µg/ml).{46854} It inhibits cell wall synthesis in B. subtilis when used at a concentration of 0.5 µg/ml.{46853} Ramoplanin complex is effective against systemic S. pyogenes, S. pneumoniae, and S. aureus infections in mice with ED50 values of 0.081, 0.14, and approximately 25 mg/kg per day, respectively.
Brand:CaymanSKU:28189 - 10 mgAvailable on backorder
Ramoplanin complex is a mixture of ramoplanin A1, -A2, and -A3 originally isolated from Actinoplanes that has antibacterial activity.{46853,46854,46855} Ramoplanin complex is active against clinical isolates of the Gram-positive bacteria S. aureus, S. pyogenes, S. pneumoniae, and S. faecalis (MICs = 0.016-2 µg/ml) but not Gram-negative bacteria or C. albicans (MICs = ≥128 µg/ml).{46854} It inhibits cell wall synthesis in B. subtilis when used at a concentration of 0.5 µg/ml.{46853} Ramoplanin complex is effective against systemic S. pyogenes, S. pneumoniae, and S. aureus infections in mice with ED50 values of 0.081, 0.14, and approximately 25 mg/kg per day, respectively.
Brand:CaymanSKU:28189 - 100 mgAvailable on backorder
Ramoplanin complex is a mixture of ramoplanin A1, -A2, and -A3 originally isolated from Actinoplanes that has antibacterial activity.{46853,46854,46855} Ramoplanin complex is active against clinical isolates of the Gram-positive bacteria S. aureus, S. pyogenes, S. pneumoniae, and S. faecalis (MICs = 0.016-2 µg/ml) but not Gram-negative bacteria or C. albicans (MICs = ≥128 µg/ml).{46854} It inhibits cell wall synthesis in B. subtilis when used at a concentration of 0.5 µg/ml.{46853} Ramoplanin complex is effective against systemic S. pyogenes, S. pneumoniae, and S. aureus infections in mice with ED50 values of 0.081, 0.14, and approximately 25 mg/kg per day, respectively.
Brand:CaymanSKU:28189 - 250 mgAvailable on backorder
Ramoplanin complex is a mixture of ramoplanin A1, -A2, and -A3 originally isolated from Actinoplanes that has antibacterial activity.{46853,46854,46855} Ramoplanin complex is active against clinical isolates of the Gram-positive bacteria S. aureus, S. pyogenes, S. pneumoniae, and S. faecalis (MICs = 0.016-2 µg/ml) but not Gram-negative bacteria or C. albicans (MICs = ≥128 µg/ml).{46854} It inhibits cell wall synthesis in B. subtilis when used at a concentration of 0.5 µg/ml.{46853} Ramoplanin complex is effective against systemic S. pyogenes, S. pneumoniae, and S. aureus infections in mice with ED50 values of 0.081, 0.14, and approximately 25 mg/kg per day, respectively.
Brand:CaymanSKU:28189 - 50 mgAvailable on backorder
Ramosetron is a potent and selective antagonist of the serotonin (5-HT) receptor subtype 5-HT3 (Ki = 0.06 nM).{25619,25621} It has little or no effect at other 5-HT receptor subtypes or at adrenergic or histamine receptors.{25619} Ramosetron competitively blocks serotonin-mediated contraction of the colon.{25619} It has applications in ameliorating diarrhea-predominant inflammatory bowel syndrome and postoperative nausea and vomiting.{25618,25620}
Brand:CaymanSKU:- Ramosetron is a potent and selective antagonist of the serotonin (5-HT) receptor subtype 5-HT3 (Ki = 0.06 nM).{25619,25621} It has little or no effect at other 5-HT receptor subtypes or at adrenergic or histamine receptors.{25619} Ramosetron competitively blocks serotonin-mediated contraction of the colon.{25619} It has applications in ameliorating diarrhea-predominant inflammatory bowel syndrome and postoperative nausea and vomiting.{25618,25620}
Brand:CaymanSKU:- Ramosetron is a potent and selective antagonist of the serotonin (5-HT) receptor subtype 5-HT3 (Ki = 0.06 nM).{25619,25621} It has little or no effect at other 5-HT receptor subtypes or at adrenergic or histamine receptors.{25619} Ramosetron competitively blocks serotonin-mediated contraction of the colon.{25619} It has applications in ameliorating diarrhea-predominant inflammatory bowel syndrome and postoperative nausea and vomiting.{25618,25620}
Brand:CaymanSKU:- Ramosetron is a potent and selective antagonist of the serotonin (5-HT) receptor subtype 5-HT3 (Ki = 0.06 nM).{25619,25621} It has little or no effect at other 5-HT receptor subtypes or at adrenergic or histamine receptors.{25619} Ramosetron competitively blocks serotonin-mediated contraction of the colon.{25619} It has applications in ameliorating diarrhea-predominant inflammatory bowel syndrome and postoperative nausea and vomiting.{25618,25620}
Brand:CaymanSKU:-
Ranitidine is a histamine H2 receptor antagonist.{27474} It reverses histamine-induced relaxation of isolated rat uterine horn (pA2 = 6.9) as well as histamine-induced increases in contraction frequency in isolated guinea pig right atrium (pA2 = 7.2). Ranitidine (0.03-3 mg/kg, i.v.) inhibits histamine-and pentagastrin-induced gastric acid secretion in a dose-dependent manner in anesthetized rats. Formulations containing ranitidine have been used in the treatment and preventrion of heartburn and gastroesophageal reflux disease (GERD).
Brand:CaymanSKU:-Out of stock
Ranitidine is a histamine H2 receptor antagonist.{27474} It reverses histamine-induced relaxation of isolated rat uterine horn (pA2 = 6.9) as well as histamine-induced increases in contraction frequency in isolated guinea pig right atrium (pA2 = 7.2). Ranitidine (0.03-3 mg/kg, i.v.) inhibits histamine-and pentagastrin-induced gastric acid secretion in a dose-dependent manner in anesthetized rats. Formulations containing ranitidine have been used in the treatment and preventrion of heartburn and gastroesophageal reflux disease (GERD).
Brand:CaymanSKU:-Out of stock
Ranitidine-d6 is intended for use as an internal standard for the quantification of ranitidine (Item No. 16939) by GC- or LC-MS. Ranitidine is a histamine H2 receptor antagonist.{27474} It reverses histamine-induced relaxation of isolated rat uterine horn (pA2 = 6.9) as well as histamine-induced increases in contraction frequency in isolated guinea pig right atrium (pA2 = 7.2). Ranitidine (0.03-3 mg/kg, i.v.) inhibits histamine-and pentagastrin-induced gastric acid secretion in a dose-dependent manner in anesthetized rats. Formulations containing ranitidine have been used in the treatment and prevention of heartburn and gastroesophageal reflux disease (GERD).
Brand:CaymanSKU:22583 -Out of stock
Ranitidine-d6 is intended for use as an internal standard for the quantification of ranitidine (Item No. 16939) by GC- or LC-MS. Ranitidine is a histamine H2 receptor antagonist.{27474} It reverses histamine-induced relaxation of isolated rat uterine horn (pA2 = 6.9) as well as histamine-induced increases in contraction frequency in isolated guinea pig right atrium (pA2 = 7.2). Ranitidine (0.03-3 mg/kg, i.v.) inhibits histamine-and pentagastrin-induced gastric acid secretion in a dose-dependent manner in anesthetized rats. Formulations containing ranitidine have been used in the treatment and prevention of heartburn and gastroesophageal reflux disease (GERD).
Brand:CaymanSKU:22583 -Out of stock
Ranolazine is a piperazine derivative with cardioprotective activity.{25575,25576,25577,42415} It reduces the late sodium current (INa) in mouse myocytes expressing the long QT syndrome 3 mutant sodium channel DKPQ, ventricular myocytes isolated from a canine model of heart failure, guinea pig ventricular myocytes exposed to hydrogen peroxide or anemone toxin-II, and HEK293 cells expressing human Nav1.5 channels (IC50s = 5.9-15 μM) as well as the late potassium current (IKr) in canine ventricular myocytes and HEK293 cells (IC50s = 11.5 and 14.4 μM, respectively).{25575,25576} Ranolazine also inhibits radioligand binding to α1-, β1-, and β2-adrenergic receptors (Kis = 8.2-19.5, 1.4-8.6, and 0.5-14.8 μM, respectively).{25576} In vivo, ranolazine (480 μg/kg per min) reduces clofilium-induced prolongation of the QTc interval and Torsade de Pointes (TdP) in rabbits.{25577} Ranolazine also reduces interstitial collagen deposition as well as atrial natriuretic peptide (ANP; Item Nos. 24539 | 24276), connective tissue growth factor (CTGF), brain natriuretic peptide (BNP; Item No. 24541), and matrix metalloproteinase-2 (MMP-2) mRNA levels, and prevents left ventricular dilation in a mouse model of cardiotoxicity induced by doxorubicin (Item No. 15007).{42415}
Brand:CaymanSKU:- Ranolazine is a piperazine derivative with cardioprotective activity.{25575,25576,25577,42415} It reduces the late sodium current (INa) in mouse myocytes expressing the long QT syndrome 3 mutant sodium channel DKPQ, ventricular myocytes isolated from a canine model of heart failure, guinea pig ventricular myocytes exposed to hydrogen peroxide or anemone toxin-II, and HEK293 cells expressing human Nav1.5 channels (IC50s = 5.9-15 μM) as well as the late potassium current (IKr) in canine ventricular myocytes and HEK293 cells (IC50s = 11.5 and 14.4 μM, respectively).{25575,25576} Ranolazine also inhibits radioligand binding to α1-, β1-, and β2-adrenergic receptors (Kis = 8.2-19.5, 1.4-8.6, and 0.5-14.8 μM, respectively).{25576} In vivo, ranolazine (480 μg/kg per min) reduces clofilium-induced prolongation of the QTc interval and Torsade de Pointes (TdP) in rabbits.{25577} Ranolazine also reduces interstitial collagen deposition as well as atrial natriuretic peptide (ANP; Item Nos. 24539 | 24276), connective tissue growth factor (CTGF), brain natriuretic peptide (BNP; Item No. 24541), and matrix metalloproteinase-2 (MMP-2) mRNA levels, and prevents left ventricular dilation in a mouse model of cardiotoxicity induced by doxorubicin (Item No. 15007).{42415}
Brand:CaymanSKU:-